# A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

> **NCT00535782** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 132 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Placebo
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00535782
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-31
- **Primary completion:** 2008-09-30
- **Final completion:** 2011-01-31
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535782, "A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00535782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*